Despite not being a primary aim of the study, by collecting participant characteristics we saw clinically significant improvements in physical health (weight and HbA1c), of similar magnitude to that seen in trials of GLP-1 receptor agonists in obesity [35] and T2D and overweight [36, 37]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.